11/30/2021 | Press release | Distributed by Public on 11/30/2021 13:10
Fried Frank acted as counsel to SVB Leerink LLC as financial advisor to Dicerna Pharmaceuticals, Inc. (Dicerna), in its US$3.3 billion sale to Novo Nordisk. Dicerna is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Novo Nordisk is a leading global healthcare company headquartered in Denmark. Novo Nordisk and Dicerna have been parties to a research collaboration since 2019 to discover and develop RNAi therapies using Dicerna's proprietary GalXC™ RNAi platform technology. The transaction is expected to close in the fourth quarter of 2021.
The Fried Frank team was led by corporate partner Warren S. de Wied.